The Longevity Reality Radar
46 approaches, rated by evidence.

PCSK9 base editing (VERVE-102)

PCSK9 base editing (Verve VERVE-102). Heart & cardiovascular. Reviewed Jul 2026.

One infusion durably lowered LDL in a small Phase 1, but there is no heart-attack outcome data and the long-term safety of a permanent edit is not established.

Stage
Phase 1
Rung: In human trials. Phase 1 to 3. Being tested in people now. Most will not make it.
Evidence grade
C
small Phase 1
Small or uncontrolled human data, or strong animal data. How grades work.

What it is

A single IV infusion of an mRNA adenine base-editor that permanently switches off the PCSK9 gene in the liver, durably lowering LDL cholesterol.

The evidence

Phase 1 data in familial hypercholesterolemia / premature coronary disease show meaningful, durable LDL reduction after one dose. Long-term safety of permanent edits still being established.

What you can do today

Outside a registered clinical trial, this is not something you can responsibly get. If it is relevant to you, the route is a trial: ask your specialist, or search a trial registry such as ClinicalTrials.gov for studies you may qualify for.

Sources

No primary paper or registry record is linked for this entry yet. The evidence summary names the studies it relies on.

Change history

No ladder moves or corrections logged for this entry yet. Changes are dated on the change log.

Related

More in Heart & cardiovascular

All 3 in Heart & cardiovascular.

  • Dietary nitrate and nitric oxideGrade B, blood pressure RCTs. Established, for blood pressure only.Lowers systolic blood pressure by about 3 to 5 mmHg in randomised trials, but there is no outcome data showing it prevents heart attacks, deaths or plaque.
  • Lp(a) lowering drugsGrade B, surrogate RCTs. Phase 3, outcome trials.Cuts Lp(a) by 80 to 98% in trials, but outcome trials have not yet shown that this prevents heart attacks or strokes.